Paper Details

  1. Home
  2. Paper Details

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.

Author: HoritaNobuyuki, InoueMiyo, KanekoTakeshi, KudoMakoto, NagaiKenjiro, NagakuraHideyuki, NakashimaKentaro, SatoTakashi, ShibataYuji, ShinkaiMasaharu, TashiroKen, TsukaharaToshinori, UshioRyota, WatanabeHiroki, YamamotoMasaki

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study reviewed 14 articles on the use of topotecan as a second-line chemotherapy for relapsed small-cell lung carcinoma (SCLC). The results showed that topotecan may be a promising treatment for sensitive-relapse SCLC, but less effective for refractory relapse SCLC. The most common adverse events were hematological, such as neutropenia, thrombopenia, and anemia.
Paper Details　
Original Abstract of the Article :
Topotecan is the most reliable chemotherapy regimen for relapsed small-cell lung carcinoma (SCLC). The efficacy and adverse effects of topotecan as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for 6-month over-all survival...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614251/

データ提供：米国国立医学図書館（NLM）

Topotecan for Relapsed Small-Cell Lung Cancer: A Meta-Analysis

Navigating the desert of cancer treatment is a difficult journey, filled with uncertainty and hope. This meta-analysis delves into the effectiveness of topotecan, a chemotherapy drug, for treating relapsed small-cell lung carcinoma (SCLC). Like a seasoned explorer charting a new route, researchers combined data from multiple studies to assess the efficacy and safety of this treatment.

Topotecan and Relapsed SCLC

The meta-analysis revealed that topotecan can provide a modest improvement in survival rates for patients with sensitive-relapse SCLC. However, for patients with refractory relapse SCLC, the outcomes were less favorable. The authors also reported that the most common side effects of topotecan were hematologic, similar to the effects of a harsh desert environment on a camel's body. These findings highlight the importance of personalized treatment approaches, taking into account the specific characteristics of the tumor and the patient's overall health.

The Importance of Personalized Treatment

The results of this meta-analysis emphasize the need for individualized treatment plans, just as a camel navigating a desert chooses its path based on the specific conditions it encounters. For patients with relapsed SCLC, a multidisciplinary approach is crucial, involving oncologists, nurses, and other healthcare professionals. This team approach can help ensure that patients receive the most appropriate and effective care, optimizing their chances of success in their fight against cancer.

Dr.Camel's Conclusion

The desert of cancer research is constantly evolving, with new treatments and strategies emerging all the time. This meta-analysis provides valuable insights into the potential benefits and risks of topotecan for treating relapsed SCLC. It reminds us that the journey of cancer treatment is complex and individualized, and we must continue to explore new pathways, seeking the most effective therapies for each patient.
Date :
  1. Date Completed 2016-09-14
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26486755

DOI: Digital Object Identifier

PMC4614251

Related Literature

Article Analysis
・Side Effects of topotecan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.